Efficacy of baricitinib in the treatment of rheumatoid arthritis

Expert Opinion on Pharmacotherapy

Volumn 18, Issue 13, 2017, Pages 1399-1407

  Richez, Christophe ^a,b   Truchetet, Marie Elise ^a,b   Kostine, Marie ^a   Schaeverbeke, Thierry ^a   Bannwarth, Bernard ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

baricitinib; herpes zoster virus; JAK; monotherapy; Rheumatoid arthritis

Indexed keywords

BARICITINIB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; SULFONAMIDE;

AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; DIGESTIVE SYSTEM PERFORATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FACIAL NERVE PARALYSIS; HERPES ZOSTER; HUMAN; INFECTION; MAJOR ADVERSE CARDIAC EVENT; MALIGNANT NEOPLASM; MAXIMUM PLASMA CONCENTRATION; MELANOMA; NAUSEA; NEUTROPENIA; NON MELANOMA SKIN CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; JANUS KINASE 1; JANUS KINASE 2; SULFONAMIDES; TREATMENT OUTCOME;

EID: 85026406532     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2017.1359256     Document Type: Article

References (43)

1. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis:estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–1322.
2. Firestein GS, McInnes IB., Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183–196.
3. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3–5.
4. Smolen JS, Aletaha D, McInnes IB., Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.• An update of the pathogenesis of RA and its therapeutic implications.
5. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis:a prospective study. Lancet. 2002;359(9313):1173–1177.
6. Wasko MC, Dasgupta A, Hubert H, et al. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis and Rheumatism. 2013;65(2):334–342.
7. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2016 update. Ann Rheum Dis. 2017;76:960–977.
8. Singh JA, Saag KG, Bridges SL, Jr., et al. 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
9. Shahouri SH, Michaud K, Mikuls TR, et al. Remission of rheumatoid arthritis in clinical practice:application of the American College Of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis and Rheumatism. 2011;63(11):3204–3215.
10. Prince FH, Bykerk VP, Shadick NA, et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther. 2012;14(2):R68.
11. Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy:a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016;43(3):504–511.
12. Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333–340.
13. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252.
14. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs:results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88–95.
15. Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506–517.
16. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662.
17. Greenwald MK, Fidelus-Gort R, Levy R, et al. A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis [abstract]. Arthritis Rheum. 2010;62(Suppl10):2172.
18. Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384.•• Recent review of the knowledge of JAK-STAT signaling.
19. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36.• Review of the involvement of JAKs in inflammatory diseases.
20. Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54(12):1354–1361.
21. Markham A. Baricitinib:first global approval. Drugs. 2017;77(6):697–704.
22. Vaddi K, Luchi M. JAK inhibition for the treatment of rheumatoid arthritis:a new era in oral DMARD therapy. Expert Opin Investig Drugs. 2012;21(7):961–973.
23. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis:preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298–5307.
24. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038.
25. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234–243.
26. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93(3):373–383.
27. Migita K, Izumi Y, Torigoshi T, et al. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol. 2013;174(3):356–363.
28. European Medicines Agency. Committee for medicinal products for human use (CHMP). Olumiant assessment report. Dec 15. AfhweeedeG.
29. EMABOsopcAf. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004085/WC500223723.pdf
30. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019.
31. Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2016;76(4):694–700.
32. Taylor P, Zhu B, Gaich C, et al. SAT0055. Baricitinib showed rapid and greater reduction in pain compared to adalimumab or placebo in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis. 2017;76(Suppl2):788.
33. Fautrel B, van de Laar MB, Kirkham B, et al. THU0081. Differences in patient-reported outcomes between baricitinib and comparators among patients with rheumatoid arthritis who achieved low disease activity or remission [abstract]. Ann Rheum Dis. 2017;76(Suppl2):230.
34. Smolen J, Genovese MC, Takeuchi T, et al. THU0166. Safety profile of baricitinib in patients with active RA:an integrated analysis [abstract]. Ann Rheum Dis. 2016;75(Suppl2):243–244.
35. Winthrop KL, Lindsey S, Weinblatt M, et al. Herpes zoster in patients with moderate to severe rheumatoid arthritis treated with baricitinib [abstract]. Arthritis Rheumatol. 2016;68(suppl 10, abstr 3027).
36. Tanaka Y, Fleischmann R, Schiff M, et al. THU0209. Characterization of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in a phase 3 study (RA-beam). Ann Rheum Dis. 2016;75(Suppl2):262.
37. Emery PMI, Genovese MC, Smolen JS, et al. Characterization of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies [abstract]. Arthritis Rheumatol. 2015;67(suppl 10, abstr 1047).
38. Bannwarth B, Kostine M, Poursac N. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2013;9(6):753–761.
39. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519.
40. Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847.
41. Louder AM, Singh A, Saverno K, et al. Patient preferences regarding rheumatoid arthritis therapies:a conjoint analysis. Am Health Drug Benefits. 2016;9(2):84–93.
42. Alten R, Kruger K, Rellecke J, et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence. 2016;10:2217–2228.
43. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years:integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253–1262.•• Long-term safety data of tofacitinib.